List of Excipients in Branded Drug PRIALT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Jazz Pharmaceuticals Inc	PRIALT	ziconotide	18860-723	METHIONINE	1969-12-31
Jazz Pharmaceuticals Inc	PRIALT	ziconotide	18860-723	SODIUM CHLORIDE	1969-12-31
ESTEVE PHARMACEUTICALS SA	PRIALT	ziconotide acetate	68118-723	METHIONINE	1969-12-31
ESTEVE PHARMACEUTICALS SA	PRIALT	ziconotide acetate	68118-723	SODIUM CHLORIDE	1969-12-31
TerSera Therapeutics LLC	PRIALT	ziconotide acetate	70720-723	METHIONINE	1969-12-31
TerSera Therapeutics LLC	PRIALT	ziconotide acetate	70720-723	SODIUM CHLORIDE	1969-12-31

PRIALT Excipient Strategy and Commercial Opportunities for Ziconotide

Last updated: August 26, 2026

PRIALT is an unusually constrained formulation opportunity. Its active ingredient, ziconotide acetate, is delivered directly into cerebrospinal fluid through an intrathecal infusion system. The approved product uses a minimal, preservative-free formulation containing ziconotide acetate, sodium chloride, and water for injection. Commercial value therefore lies less in adding conventional excipients and more in improving stability, pump compatibility, ready-to-use presentation, concentration flexibility, and pharmacy handling without increasing neurotoxicity risk.

What is PRIALT and how is it formulated?

PRIALT is an intrathecal infusion containing ziconotide, a synthetic peptide derived from omega-conotoxin MVIIA. It is approved for the management of severe chronic pain in patients who require intrathecal therapy and are intolerant of, or refractory to, other treatments [1].

Product attribute	PRIALT specification
Active ingredient	Ziconotide acetate
Dosage form	Sterile intrathecal infusion solution
Commercial strengths	100 mcg/mL and 500 mcg/5 mL
Route	Continuous intrathecal infusion
Key excipients	Sodium chloride and water for injection
Preservatives	None
pH	Approximately 4.0 to 5.0
Storage	Refrigerated, protected from light
Administration	Infusion through an implanted or external intrathecal pump
Therapeutic area	Severe chronic pain

The minimal excipient profile reflects the route of administration. Intrathecal products have a narrow tolerance for particulate matter, microbial contamination, endotoxin, pH variation, osmolality changes, and leachable substances. Excipients that are acceptable in oral, subcutaneous, or intravenous products may be unsuitable for direct cerebrospinal-fluid exposure.

What excipients are used in PRIALT?

The approved formulation contains sodium chloride for isotonicity and water for injection as the vehicle. The product is preservative-free [1].

This strategy avoids several risks:

• Benzyl alcohol and other antimicrobial preservatives can cause neurotoxicity or local irritation when introduced intrathecally.
• Surfactants can affect peptide aggregation, pump-material compatibility, and tissue tolerability.
• Buffers can alter cerebrospinal-fluid exposure to ions and change peptide stability.
• Complexing agents can modify the behavior of the peptide or interact with pump components.
• High excipient loads increase the risk of local toxicity and regulatory scrutiny.

The formulation has no need for a conventional solubilizer because ziconotide is supplied as an aqueous solution. The principal formulation challenges are peptide stability, low-dose accuracy, adsorption, container compatibility, and sterility over the intended use period.

How does the PRIALT excipient strategy affect product development?

A preservative-free aqueous formulation is commercially defensible but technically restrictive. A follow-on product must demonstrate that changes to pH, tonicity, excipients, concentration, container closure, or pump contact materials do not change the safety or performance of intrathecal delivery.

pH control

PRIALT is maintained in an acidic range. A developer considering a different pH would need to evaluate:

• Ziconotide chemical degradation.
• Peptide aggregation or precipitation.
• Adsorption to glass, plastic, tubing, and pump reservoirs.
• Local tolerability in the intrathecal space.
• Impact on cerebrospinal-fluid pH and osmolality.
• Compatibility with validated infusion systems.

A buffered formulation may improve pH control during storage, dilution, or pump administration. It could also create new risks from buffer species, ionic strength, and intrathecal tolerability. The commercial case for a buffer is therefore stronger when it solves a demonstrated stability or compatibility problem rather than merely improving laboratory robustness.

Tonicity

Sodium chloride provides the principal tonicity adjustment. A reformulation could explore alternative tonicity agents, but the benefit is limited. Sodium chloride is inexpensive, familiar to hospitals, and widely accepted for parenteral use. Replacing it would create a higher regulatory and toxicological burden without an obvious clinical advantage.

Peptide adsorption

Low-concentration peptide solutions can adsorb to containers, tubing, filters, and pump components. This problem is commercially relevant because PRIALT is used at individualized doses and may be diluted before infusion. Potential approaches include:

• Low-binding polymeric containers.
• Surface-treated tubing.
• Alternative elastomer formulations.
• Controlled use of low concentrations of peptide-compatible surfactants.
• Preconditioning or validated flush procedures.

Surfactants require particular caution in intrathecal products. A formulation that improves recovery from tubing but introduces neurotoxicity, aggregation, or extractables risk would have limited commercial value.

Antioxidant and chelator use

Antioxidants and chelating agents could theoretically reduce oxidation or metal-catalyzed degradation. Their use is not part of the approved PRIALT formulation and would require a clear benefit-risk rationale. Intrathecal administration makes the toxicology burden substantially higher than for standard systemic products.

What formulations are protected by PRIALT’s product strategy?

The strongest formulation differentiation is likely to come from the full product system rather than from sodium chloride or water for injection. Relevant protection areas include:

1. A sterile, preservative-free ziconotide solution at a defined concentration and pH.
2. A ready-to-use concentration designed for a specific pump platform.
3. A diluted presentation with validated in-use stability.
4. A low-adsorption container, tubing, or reservoir system.
5. A formulation that reduces peptide loss during long-duration infusion.
6. A high-concentration presentation that reduces pharmacy manipulation.
7. A formulation with improved refrigerated or room-temperature stability.
8. A combination of ziconotide concentration, pump reservoir, administration set, and storage conditions.

Patent value depends on claim scope, priority dates, prosecution history, and remaining term. Broad claims covering ziconotide itself or basic aqueous solutions are more vulnerable to expiration and invalidity challenges than narrow claims directed to specific stability, container, device, or manufacturing parameters. The FDA label identifies the approved formulation and handling requirements but does not establish the complete patent estate [1].

What commercial opportunities exist for PRIALT excipients?

Ready-to-use intrathecal presentations

Hospitals and specialty pharmacies face operational risks when diluting concentrated products. A ready-to-use presentation could reduce manipulation, calculation errors, aseptic preparation time, and waste. Commercial formats could include:

• Pre-diluted bags or syringes.
• Pump-specific cartridges.
• Single-use pharmacy containers.
• Multiple concentrations aligned with common starting and maintenance doses.

The main limitation is shelf life. A diluted product must maintain potency, sterility, clarity, and pump compatibility through the labeled storage and administration period.

High-concentration products

A higher concentration could reduce infusion volume and extend the interval between pump refills. This could benefit patients with implanted pumps and reduce procedure frequency. The development risks include dose-delivery accuracy, local concentration exposure, peptide solubility, aggregation, adsorption, and pump calibration.

A high-concentration product may be commercially attractive if it supports refill intervals that are materially longer than the current presentation. It would require evidence that concentration changes do not increase neurological adverse events or compromise infusion accuracy.

Low-binding delivery systems

A combined formulation and device product could address peptide loss in reservoirs and tubing. The opportunity is strongest where a developer can show reproducible delivery over the full pump-use period. Claims could potentially cover the combination of formulation composition, material selection, and operating conditions.

This pathway is more defensible than a simple excipient substitution because the commercial benefit arises from system performance. It may also support device-related exclusivity and contracting advantages with specialty pain centers.

Improved storage and handling

PRIALT requires refrigerated storage and protection from light [1]. A product with longer room-temperature stability could lower cold-chain costs and reduce pharmacy discard. Potential technologies include:

• Stabilizing buffers.
• Peptide-compatible surfactants.
• Alternative container closures.
• Lyophilized ziconotide for reconstitution.
• Improved oxygen and moisture barriers.

A lyophilized product would introduce reconstitution steps and could undermine the main handling advantage. It is more likely to create value in markets with weak cold-chain infrastructure than in hospitals already equipped to manage refrigerated sterile products.

Compounded and outsourced presentations

Intrathecal therapy frequently involves patient-specific dosing. Outsourcing facilities and specialty pharmacies may have demand for validated compounded concentrations. A manufacturer could pursue a finished pharmaceutical product, a pharmacy-use kit, or a contract manufacturing model.

The regulatory boundary is important. A 503B outsourcing facility product is not equivalent to an FDA-approved finished drug, and a compounded formulation does not automatically obtain the same clinical, manufacturing, or intellectual-property position as PRIALT. FDA’s compounding framework governs the conditions under which outsourcing facilities may produce sterile drugs [2].

When does PRIALT lose exclusivity?

PRIALT was approved by the FDA in 2004 [1]. Regulatory exclusivity periods associated with the original approval have expired. The remaining commercial barriers are more likely to involve formulation, manufacturing, device compatibility, clinical evidence, and market scale than new-drug exclusivity.

Patent expiry dates must be assessed patent by patent. Relevant categories include:

• Ziconotide composition patents.
• Synthetic manufacturing patents.
• Pharmaceutical composition patents.
• Stability and storage patents.
• Intrathecal administration patents.
• Pump and reservoir compatibility patents.
• Method-of-use patents for chronic pain.

The FDA Orange Book is the principal source for listed patents and regulatory exclusivity associated with approved drug products [3]. A generic applicant would need to assess whether any listed patent remains relevant and whether a Paragraph IV certification is commercially viable.

Are Paragraph IV challenges or biosimilar risks relevant to PRIALT?

Paragraph IV risk

A follow-on ziconotide product could use an abbreviated pathway if it meets the applicable requirements for a generic product. Because PRIALT is a peptide drug delivered intrathecally, the applicant would face more than a conventional oral-tablet equivalence exercise. Key issues include:

• Same active ingredient and strength.
• Sterility and endotoxin control.
• Peptide identity and impurity profile.
• Container and pump compatibility.
• Stability after dilution.
• Drug delivery accuracy.
• Labeling and administration instructions.

A Paragraph IV challenge would be most credible against unexpired listed patents that materially cover the proposed product. Expired basic composition claims would not by themselves prevent market entry.

Biosimilar risk

Ziconotide is a chemically synthesized peptide, not a monoclonal antibody or other biologic normally evaluated under the biosimilar pathway. Biosimilar competition is therefore not the primary risk category. The more relevant threat is a generic, hybrid, or 505(b)(2) product supported by comparative pharmaceutical and delivery-system data.

How strong is the PRIALT patent estate?

The formulation patent estate should be viewed as moderate in commercial relevance but difficult to assess from the label alone. A simple formulation based on ziconotide, sodium chloride, and water for injection is technically narrow and potentially vulnerable once core patents expire. Stronger protection may attach to:

• Defined stability under pump-use conditions.
• Specific reservoir or tubing materials.
• Reduced adsorption.
• Ready-to-use diluted products.
• High-concentration formulations.
• Combination claims covering formulation and pump.
• Manufacturing controls for peptide impurities.

Manufacturing know-how may be as important as patents. Ziconotide synthesis requires control of peptide impurities, folding or disulfide-related attributes, residual reagents, and batch consistency. A follow-on manufacturer must also qualify sterile filling, low-dose assay methods, and container closure systems suitable for intrathecal use.

What FDA regulatory status applies to PRIALT follow-on products?

A conventional generic pathway may be possible if the proposed product matches the reference product sufficiently. A 505(b)(2) application may be more practical for a product with a different concentration, excipient system, container, pump, or administration method. A reformulated product could require additional nonclinical or clinical support if the change affects intrathecal exposure or safety.

The principal FDA review issues are likely to include:

• Comparative quality and impurity characterization.
• Sterility assurance and endotoxin limits.
• In-use stability in the proposed pump.
• Extractables and leachables.
• Particulate matter.
• Dose-delivery accuracy.
• Intrathecal tolerability.
• Human factors for pharmacy preparation and pump refill.

How does PRIALT compare with other intrathecal pain products?

Product	Active ingredient	Formulation opportunity	Primary competitive issue
PRIALT	Ziconotide	Preservative-free aqueous peptide solution	Intrathecal safety and pump handling
Intrathecal morphine products	Morphine sulfate	Established sterile solutions, often preservative-sensitive by route	Opioid tolerance, respiratory depression, dependence
Baclofen products	Baclofen	Pump-specific sterile presentations	Spasticity indication and device dependence
Compounded intrathecal mixtures	Varies	Patient-specific concentration and combinations	Quality consistency, sterility, regulatory status

PRIALT’s strongest clinical differentiation is avoidance of opioid mechanism and opioid-related adverse effects. Its commercial limitation is a demanding titration profile and the requirement for intrathecal administration. Excipient innovation cannot remove the core need for an implanted or external pump, but it can reduce handling friction and improve delivery reliability.

What generic launch scenarios exist for PRIALT?

Three launch scenarios are commercially plausible:

1. A direct generic solution matching the reference formulation. This would create the lowest differentiation and the greatest price pressure.
2. A 505(b)(2) product with a new concentration, storage profile, container, or pump presentation. This offers stronger differentiation but requires more development work.
3. A combined drug-device product with low-binding materials and validated delivery performance. This has the highest technical barrier and potentially the strongest commercial defensibility.

The market is specialized, so revenue potential depends on the installed pump base, refill frequency, number of treated patients, reimbursement, and specialist adoption. A lower-cost generic could expand access but may not generate the scale seen in high-volume oral or injectable medicines.

Key Takeaways

• PRIALT uses a minimal, preservative-free formulation of ziconotide acetate, sodium chloride, and water for injection.
• The intrathecal route sharply limits acceptable excipient choices.
• Sodium chloride is unlikely to provide meaningful formulation differentiation by itself.
• The strongest commercial opportunities involve ready-to-use presentations, high concentrations, low-binding materials, pump compatibility, and improved in-use stability.
• Ziconotide is a synthetic peptide, so generic or 505(b)(2) competition is more relevant than biosimilar competition.
• Patent value is likely to shift from basic composition claims toward stability, delivery-system, container, and manufacturing claims.
• A follow-on product must solve intrathecal sterility, adsorption, leachables, dose accuracy, and pump-compatibility requirements.
• The commercial market is specialized, making operational convenience and refill economics more important than broad excipient novelty.

FAQs About PRIALT Excipient and Formulation Opportunities

Can preservatives be added to PRIALT?

Preservatives are generally unsuitable for direct intrathecal administration because of neurotoxicity and local-tolerability concerns. A preservative-free strategy is the appropriate benchmark for development.

Could PRIALT be reformulated as a prefilled syringe?

A prefilled syringe could reduce pharmacy preparation, but the product would need validated compatibility with the intended pump, syringe materials, storage conditions, transfer procedure, and dose-delivery system.

Is a lyophilized ziconotide product commercially attractive?

Lyophilization could improve storage stability, but reconstitution adds handling steps and aseptic risk. Its value would depend on whether the resulting shelf-life or geographic reach offsets the operational complexity.

Can a manufacturer market a higher-strength ziconotide product?

Potentially, but the product would require evidence supporting solubility, aggregation control, dose accuracy, intrathecal tolerability, and compatibility with the intended pump and administration set.

What is the main intellectual-property barrier for a PRIALT generic?

The main barrier is unlikely to be a conventional excipient patent. More relevant risks involve unexpired claims covering formulation stability, pump compatibility, container materials, administration systems, or manufacturing controls.

References

1. U.S. Food and Drug Administration. (2023). PRIALT (ziconotide acetate) injection, prescribing information.
2. U.S. Food and Drug Administration. (2023). Current good manufacturing practice, quality systems approach, and compounding outsourcing facilities guidance.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.